Vera Therapeutics Inc
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company's lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-adm… Read more
Vera Therapeutics Inc (VERA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.155x
Based on the latest financial reports, Vera Therapeutics Inc (VERA) has a cash flow conversion efficiency ratio of -0.155x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-61.91 Million) by net assets ($398.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Vera Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Vera Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Vera Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vera Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Goodyear Tire & Rubber Co
NASDAQ:GT
|
0.444x |
|
HD Hyundai Marine Solution
KO:443060
|
N/A |
|
COUNTRY GARDEN SVDL-0001
F:75H
|
N/A |
|
BELLRING BRANDS DL-01
F:D51
|
N/A |
|
Inaba Denki Sangyo Co.Ltd.
PINK:IBADF
|
N/A |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
0.077x |
|
Veeco Instruments Inc
NASDAQ:VECO
|
0.018x |
|
Pandox AB (publ)
PINK:PNDXF
|
0.052x |
Annual Cash Flow Conversion Efficiency for Vera Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Vera Therapeutics Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $577.15 Million | $-134.68 Million | -0.233x | +74.26% |
| 2023-12-31 | $101.69 Million | $-92.18 Million | -0.907x | -3.14% |
| 2022-12-31 | $76.91 Million | $-67.60 Million | -0.879x | -158.00% |
| 2021-12-31 | $69.59 Million | $-23.71 Million | -0.341x | -187.44% |
| 2020-12-31 | $-89.35 Million | $-34.81 Million | 0.390x | +38.39% |
| 2019-12-31 | $-36.55 Million | $-10.29 Million | 0.282x | -- |